Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis

Osteoporosis International

Volumn 26, Issue 3, 2015, Pages 1193-1202

  Sakai, A ^a   Ito, M ^b   Tomomitsu, T ^c   Tsurukami, H ^d   Ikeda, S ^e   Fukuda, F ^f   Mizunuma, H ^g   Inoue, T ^h   Saito, H ⁱ   Nakamura, T ^j  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c Kawasaki College of Allied Health Professions   (Japan)

^d Tsurukami Clinic of Orthopaedics and Rheumatology   (Japan)

^e Ken Ai Memorial Hospital   (Japan)

^f Kitakyushu General Hospital   (Japan)

^g HIROSAKI UNIVERSITY   (Japan)

^h TAISHO PHARMACEUTICAL CO LTD   (Japan)

ⁱ CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^j NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

more..

Author keywords

Bisphosphonate; Bone mineral density; Bone turnover markers; Eldecalcitol; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL PROPEPTIDE OF TYPE 1 PROCOLLAGEN; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; ELDECALCITOL; PARATHYROID HORMONE; UNCLASSIFIED DRUG; VITAMIN D; BONE DENSITY CONSERVATION AGENT; COLECALCIFEROL;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; BREAST DISEASE; COMPARATIVE STUDY; CONNECTIVE TISSUE DISEASE; CYST; DRUG EFFICACY; DRUG SAFETY; EAR DISEASE; EYE DISEASE; FEMALE; FEMUR NECK; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HIP; HUMAN; IMMUNOPATHOLOGY; INFECTION; INNER EAR DISEASE; JAPANESE (PEOPLE); KIDNEY DISEASE; LUMBAR SPINE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; POLYP; PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; SKIN DISEASE; SPINE FRACTURE; THORAX DISEASE; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; BONE REMODELING; COMBINATION DRUG THERAPY; CONTROLLED STUDY; JAPAN; LUMBAR VERTEBRA; METABOLISM; MIDDLE AGED; OSTEOPOROSIS; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALENDRONATE; BIOMARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCIUM; CHOLECALCIFEROL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JAPAN; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; TREATMENT OUTCOME; VITAMIN D;

EID: 84925497236     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2991-z     Document Type: Article

References (33)

1. Miyamoto K, Murayama E, Ochi K, Watanabe H, Kubodera N (1993) Synthetic studies of vitamin D analogues. XIV. Synthesis and calcium regulating activity of vitamin D3 analogues bearing a hydroxyalkoxy group at the 2 beta-position. Chem Pharm Bull (Tokyo) 41:1111–1113
2. Matsumoto T, Miki T, Hagino H, Sugimoto T, Okamoto S, Hirota T, Tanigawara Y, Hayashi Y, Fukunaga M, Shiraki M, Nakamura T (2005) A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 90:5031–5036
3. Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures–a randomized, active comparator, double-blind study. Bone 49:605–612. doi:10.1016/j.bone.2011.07.011
4. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795
5. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH (2007) Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 1117:209–257
6. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H, Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337
7. Mori S, Soen S, Hagino H, Nakano T, Ito M, Fujiwara S, Kato Y, Tokuhashi Y, Togawa D, Endo N, Sawaguchi T, Committee for Vertebral Fracture Evaluation (2013) Justification criteria for vertebral fractures: year 2012 revision. J Bone Miner Metab 31:258–261. doi:10.1007/s00774-013-0441-1
8. Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res 11:984–996
9. Harada S, Mizoguchi T, Kobayashi Y, Nakamichi Y, Takeda S, Sakai S, Takahashi F, Saito H, Yasuda H, Udagawa N, Suda T, Takahashi N (2012) Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J Bone Miner Res 27:461–473. doi:10.1002/jbmr.555
10. de Freitas PH, Hasegawa T, Takeda S, Sasaki M, Tabata C, Oda K, Li M, Saito H, Amizuka N (2011) Eldecalcitol, a second-generation vitamin D analog, drives bone minimodeling and reduces osteoclastic number in trabecular bone of ovariectomized rats. Bone 49:335–342. doi:10.1016/j.bone.2011.05.022
11. Kikuta J, Kawamura S, Okiji F, Shirazaki M, Sakai S, Saito H, Ishii M (2013) Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D. Proc Natl Acad Sci U S A 110:7009–7013. doi:10.1073/pnas.1218799110
12. Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan Y (2014) miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature 512:431–435. doi:10.1038/nature13375
13. Li H, Xie H, Liu W, Hu R, Huang B, Tan YF, Xu K, Sheng ZF, Zhou HD, Wu XP, Luo XH (2009) A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J Clin Invest 119:3666–3677. doi:10.1172/JCI39832
14. Lisse TS, Adams JS, Hewison M (2013) Vitamin D and microRNAs in bone. Crit Rev Eukaryot Gene Expr 23:195–214
15. Campbell MJ (2014) Vitamin D and the RNA transcriptome: more than mRNA regulation. 5:1-13. doi: 10.3389/fphys.2014.00181
16. Scott LJ (2014) Denosumab: a review of its use in postmenopausal women with osteoporosis. Drugs Aging 31:555–576. doi:10.1007/s40266-014-0191-3
17. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, Tomita A, Yamamoto K, Nagata Y, Nakashima M, Orimo H (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 10:183–192
18. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72–81. doi:10.1359/jbmr.090716
19. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153–161. doi:10.1359/jbmr.080901
20. Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S, Moffett A, Siddhanti S, Ferreira I, Ghelani P, Wagman RB, Hall JW, Bolognese MA, Benhamou CL (2013) Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 121:1291–1299. doi:10.1097/AOG.0b013e318291718c
21. Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48–54. doi:10.1016/j.bone.2013.10.006
22. Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M, Fukunaga M (2014) Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99:2599–2607. doi:10.1210/jc.2013-4175
23. Nakamura T, Shiraki M, Fukunaga M, Tomomitsu T, Santora AC, Tsai R, Fujimoto G, Nakagomi M, Tsubouchi H, Rosenberg E, Uchida S (2014) Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis—a double-blind, randomized, dose-finding study. Osteoporos Int 25:367–376. doi:10.1007/s00198-013-2398-2
24. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431–1438
25. Ravn P, Clemmesen B, Christiansen C (1999) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237–244
26. Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimäki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievänen H, Vuori I, Väänänen HK, Halleen JM (2005) Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20:1804–1812
27. Iwamoto J, Takeda T, Sato Y, Uzawa M (2005) Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis. J Bone Miner Metab 23:238–242
28. Okano T, Tsugawa N, Masuda S, Takeuchi A, Kobayashi T, Takita Y, Nishii Y (1989) Regulatory activities of 2 beta-(3-hydroxypropoxy)-1 alpha, 25-dihydroxyvitamin D3, a novel synthetic vitamin D3 derivative, on calcium metabolism. Biochem Biophys Res Commun 163:1444–1449
29. Saito H, Harada S (2014) Eldecalcitol replaces endogenous calcitriol but does not fully compensate for its action in vivo. J Steroid Biochem Mol Biol 144:189–196. doi:10.1016/j.jsbmb.2013.11.013
30. Matsumoto T, Takano T, Yamakido S, Takahashi F, Tsuji N (2010) Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism. J Steroid Biochem Mol Biol 121:261–264. doi:10.1016/j.jsbmb.2010.03.035
31. Chugai Pharmaceutical Co., Ltd. [Common Technical Document: Eldecalcitol 2.6.2.2.1.6]. http://www.info.pmda.go.jp/shinyaku/P201100025/index.html. Japanese
32. Ochi H (1998) 2β-(3-Hydroxypropoxy)1α,25-Dihydroxyvitamin D (3) (ED-71), increases bone mass by stimulating bone formation in hypophosphatemic mice. J Okayama Med Assoc 110:31–37, Japanese
33. Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM; Fracture Intervention Research Group (2006) Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21:292–299